Loading…
Lobbying Spend
—
Filings
14
Firms Hired
1
Active Period
2022–2025
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Telehealth Modernization Act of 2024
2024 · fourth_quarter · Firm: HORIZON GOVERNMENT AFFAIRS
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule including the Telehealth Modernization Act (H.R. 7623). Regulation of laboratory-developed tests, including the FDAs final rule, Docket No. FDA-2023-N-2177. Issues relating to value-based arrangements for lab testing. Issues related to the use of artificial intelligence in health care.
Client expense: — · Firm income: —
Matched citations: H.R. 7623
Telehealth Modernization Act of 2024
2024 · third_quarter · Firm: HORIZON GOVERNMENT AFFAIRS
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule including the Telehealth Modernization Act (H.R. 7623). Regulation of laboratory-developed tests, including the FDAs final rule, Docket No. FDA-2023-N-2177. Issues relating to value-based arrangements for lab testing. Issues related to the use of artificial intelligence in health care.
Client expense: — · Firm income: —
Matched citations: H.R. 7623
Telehealth Modernization Act of 2024
2024 · second_quarter · Firm: HORIZON GOVERNMENT AFFAIRS
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule including the Telehealth Modernization Act (H.R. 7623). Regulation of laboratory-developed tests, including the FDAs final rule, Docket No. FDA-2023-N-2177. Issues relating to value-based arrangements for lab testing. Issues related to the use of artificial intelligence in health care.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 7623
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023, H.R. 2369. Issues relating to value-based arrangements for lab testing. Issues related to the use of artificial intelligence in health care.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2369
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023, H.R. 2369. Issues relating to value-based arrangements for lab testing. Issues related to the use of artificial intelligence in health care.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2369
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023, H.R. 2369. Issues relating to value-based arrangements for lab testing.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2369
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023, H.R. 2369. Issues relating to value-based arrangements for lab testing.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2369
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2023, H.R. 2369. Issues relating to value-based arrangements for lab testing.
Client expense: — · Firm income: $10,000
Matched citations: H.R. 2369
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing. FDASLA Act of 2022, S. 4348.
Client expense: — · Firm income: $10,000
Matched citations: S. 2209
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing. FDASLA Act of 2022, S. 4348.
Client expense: — · Firm income: $10,000
Matched citations: S. 4348
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing. FDASLA Act of 2022, S. 4348.
Client expense: — · Firm income: $10,000
Matched citations: S. 2209
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing. FDASLA Act of 2022, S. 4348.
Client expense: — · Firm income: $10,000
Matched citations: S. 4348
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing. FDASLA Act of 2022, S. 4348.
Client expense: — · Firm income: $10,000
Matched citations: S. 2209
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing. FDASLA Act of 2022, S. 4348.
Client expense: — · Firm income: $10,000
Matched citations: S. 4348
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act (PAMA) and the clinical laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing.
Client expense: — · Firm income: $10,000
Matched citations: S. 2209
Issues related to laboratory testing, reimbursement, access, benefits, and value. At-home testing, including for COVID-19 testing. Issues relating to the Protecting Access to Medicare Act and laboratory fee schedule. Regulation of laboratory-developed tests, including the Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021, S. 2209. Issues relating to value-based arrangements for lab testing.
Client expense: — · Firm income: —
Matched citations: S. 2209
Source: Senate LDA